Piramal Pharma Stake Sale On Track
Gains Seen For Contract Business Amid Pandemic
Executive Summary
Piramal Enterprises, which is in the process of fundraising for its pharma business, says it is well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.
You may also be interested in...
Piramal Eyes 20% Pharma Stake Sale
Piramal Enterprises, one of India’s biggest conglomerates, has said it is looking to sell up to a 20% stake in its Piramal Healthcare business to raise funds for spurring growth of the division through acquisitions.
Key Trends In CDMO Space As Dissected By Piramal Pharma Solutions CEO
Piramal Pharma Solutions CEO Vivek Sharma discusses a range of issues shaping the buzzing contract development and manufacturing segment in an interview with Scrip. Heightened consolidation and attractive prospects in the area of antibody drug conjugates, where over 600 clinical trials are being conducted worldwide, are some of the trends to watch out for.
Piramal Critical Care Docks For China Push
Peter DeYoung, CEO of Piramal Critical Care
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: